NACIMBIO
Basic information
NACIMBIO TARGET SEGMENTS
- Vaccines for infectious diseases
- Plasma blood products
- HIV and chronic viral hepatitis drugs
- TB drugs. Included in Rostec State Corporation
Location:
Moscow, RussiaProducts
News
- 07.10.2026 UEC presented projects for the development of distributed generation in the African market.
- 01.09.2026 Natsimbio Holding has begun supplying flu vaccines to Russian regions.
- 20.07.2026 Botulinum toxin therapy: chronic migraine under control
- 15.06.2026 Natsimbio's bacteriophages have proven effective in treating complex surgical infections.
- 11.06.2026 Natsimbio's flu vaccines have been included in the Register of Russian Industrial Products of the Russian Ministry of Industry and Trade.
- 14.05.2026 Natsimbio Holding appointed Dmitry Kudlai as Director of Science at NPO Mikrogen.
- 30.04.2026 Natsimbio awarded students from the Voronezh State Medical University named after Burdenko for developing an edible vaccine.
- 28.04.2026 The Natsimbio holding company has registered the first Russian vaccine for adults against whooping cough, diphtheria, and tetanus.
- 09.04.2026 Natsimbio was named one of the best pharmaceutical companies in Russia by Forbes.
- 23.03.2026 Natsimbio Holding will increase supplies of measles, mumps, and rubella vaccines by 30%.
- 17.02.2026 "Where there is meaning, there is always movement."
- 13.01.2026 Natsimbio Holding has launched a new drug for the treatment of allergies on the Russian market.
- 13.11.2025 The Natsimbio holding company has completed the delivery of flu vaccines to Russian regions ahead of schedule.
- 28.07.2025 Alexander Nizovtsev has become the General Director of the Natsimbio holding
- 07.04.2025 Natsimbio's flu vaccine recognized as the most balanced of Russian drugs
- 02.04.2025 Natsimbio to Talk About Modern Approaches to the Production of Immunobiological Drugs at the GxP-Fest 2025 Festival
- 07.03.2025 Microgen has registered a children's vaccine against tick-borne encephalitis in the Republic of Belarus
- 19.02.2025 The Natsimbio holding has developed the first Russian vaccine against diphtheria, tetanus and whooping cough for adults
- 03.02.2025 Natsimbio Holding Delivers 2 Million Doses of Vaccines to Russian Regions
- 24.01.2025 Natsimbio to Launch 30 Drugs for Diagnosis and Treatment of Allergies on the Market in 2024